# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(1....
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fortress Biotech (NASDAQ:FBIO) with a Buy and maintains $24 pric...
- SEC Filing
Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the a...
Fortress Biotech, Inc. (NASDAQ:FBIO, FBIOP)))) ("Fortress"), an innovative biopharmaceutical company focused on acquiri...
Cantor Fitzgerald analyst Jennifer Kim reiterates Fortress Biotech (NASDAQ:FBIO) with a Overweight.